July 14, 2022 7:57am

I am still waiting for the “UGLY” as the Pacman algorithms are getting hungry looking at the appreciation in many cell and gene therapy equities

Pre-open indications: 9 Negative Indications and 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -1.38% or (-423 points), S&P futures are DOWN -1.31% (-50 points) and NASDAQ futures are DOWN -0.97% (-114 points) early in the pre-open – so far,


Stock futures are falling on Thursday, be prepared for a negative open,

European stocks were trading lower,

Asia Pacific stocks were mostly mixed as Hong Kong, Australia slipped



Indexes tumbled after a key inflation report showed that US consumer prices continued to surge in June. The Dow closed DOWN -208.54 points (-0.67%); the S&P closed DOWN -17 points (-0.45%) while the Nasdaq closed DOWN -17.15 points (-0.15%)

Economic Data Docket: the June producer price index and weekly jobless claims.


RegMed Investors’ (RMi) closing bell: “cell and gene therapy sector equities were a safe haven for trading in a CPI elevated session” … https://www.regmedinvestors.com/articles/12515

Ebb and flow –

Q3/22 – 1 holiday, 2 negative and 6 positive closes

Q2/22 –

June – 1 holiday, 9 positive and 11 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative Indications:

Alnylam Pharmaceuticals (ALNY) closed down -$3.15 to $142.70 with a negative -$2.92 or -2.05% pre-open indication,

Beam Therapeutics (BEAM) closed up +$2.71 to $55.59 with a negative -$0021 or -0.04% pre-open indication,

Chinook Therapeutics (KDNY) closed UP +$0.92 to $18.84 after Tuesday’s -$0.02 and Monday’s -$0.57 with a negative -$1.01 or -5.36% pre-open indication,

CRISPR Therapeutics (CRSP) closed up +$1.65 to $80.70 with a negative -$1.05 or -1.30% pre-open indication,

Editas Medicine (EDIT) closed up again +$1.75 to $16.14 after Tuesday’s +$0.57 with a negative -$0.10 or -0.62% pre-open indication,

Fate Therapeutics (FATE) closed up +$1.51 to $31.29 with a negative -$0.43 or -1.37% pre-open indication,

Ionis Pharmaceuticals (IONS) closed up =$0.65 to $37.65 with a negative -$0.76 or -2.02% pre-open indication,

Ultragenyx (RARE) closed down -$0.03 to $65.83 after Tuesday’s -$0.01 with a negative -$1.98 or -3.01% pre-open indication.

Verve Therapeutics (VERV) closed up +$2.97 to $25.17 after Tuesday’s +$1.72 with a negative -$0.70 or -2.78% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed up +$1.33 to $5.88 with 376 shares traded <3 mo. Average = 1,721 shares> after Tuesday’s +$0.03 to $4.55 with 175 shares traded, Monday’s -$1.189 with 5,387 shares traded, Friday’s -$0.55 to $5.70 with 2,334 shares traded and last Thursday’s +$0.23 to $6.25 with 4,771 shares traded.

·         BSTG seems to have the ONLY avenue to finance to utilize non-U.S. Chinese investors?

·         How much lipstick is a lot on this pig with an almost 4-year-old IND and NO clinical trial initiation?

·         WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities


The BOTTOM LINE: I try to keep it simple … and short!


Traction is a response to be oversold and a chance to revisit the position; the algorithms are lusting for the appreciation

A post “pop-up” sector session would turn recent buys into clear losses, with the sector heading back into new lows once again.

I remain cautious, “markets, like the economy, are in flux. The major indexes could go back to lows or rebound to test or even surpass the 10-week line again. They also could move sideways in a choppy fashion for an extended period. That would let the markets get more clarity on the economy and Fed rate hikes, while more bases could form. But in the short run, stocks could be very choppy, luring investors in and shaking them out. <IBD>

Be prepared, earnings or LPS (loss-per-share) sessions are on their way and many companies will be just as glad to get them out as fast-as-possible to re-set ANY trajectory in August for September.”

There is VALUE out there however, it’s about playing or betting the timing of the sector.

We are left with choosing to hang on to “our” portfolio position as it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.